Sponsors (33)
Requires Medicare coverage of guideline‑based germline cancer gene testing, deems risk‑reducing surgery medically necessary for eligible patients, and relaxes screening limits for mutation carriers.
The bill substantially expands and clarifies Medicare coverage for genetic testing, high‑risk screening, and preventive cancer surgery for beneficiaries at hereditary risk—improving detection and access—while increasing Medicare costs and creating administrative and implementation challenges that could delay care or limit some repeat testing.
Medicare beneficiaries at elevated hereditary‑cancer risk will gain comprehensive coverage for guideline‑based germline genetic testing, guideline‑recommended higher‑frequency/high‑risk screening, and risk‑reducing cancer surgeries, improving early detection and prevention for high‑risk patients.
Aligning coverage to evidence‑based oncology guidelines and explicitly applying the new rules to existing payment provisions will reduce prior‑authorization denials, simplify billing/reimbursement, and make coverage determinations more predictable for CMS, providers, and beneficiaries.
Tying coverage to established, evidence‑based guidelines helps ensure clinically appropriate testing and reduces unnecessary or low‑value genetic tests.
Expanding Medicare coverage for genetic testing, more frequent high‑risk screening, and preventive surgeries will increase Medicare spending and could raise federal health expenditures or pressure other program benefits and taxpayers.
Implementing guideline‑based coverage across contractors and providers will create administrative complexity and burden for CMS, contractors, and health systems, potentially delaying claims processing, creating transitional confusion, and slowing patient access in some cases.
The statute denies payment for repeat germline testing for the same person in some situations, which could prevent clinically indicated repeat tests and harm individual patient care.
Based on analysis of 4 sections of legislative text.
Official title: To amend title XVIII of the Social Security Act to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation in a blood relative or a personal or ancestral history suspicious for hereditary cancer, and to provide coverage of certain cancer screenings or preventive surgeries that would reduce the risk for individuals with a germline (inherited) mutation associated with a high risk of developing a preventable cancer.
Introduced July 23, 2025 by Debbie Wasserman Schultz · Last progress July 23, 2025
Adds Medicare coverage for germline (hereditary) cancer gene testing for people with a personal or family history or other findings suspicious for hereditary cancer. It makes risk‑reducing surgery for guideline‑eligible patients explicitly a covered, medically necessary service and requires Medicare to lift or relax screening frequency limits for beneficiaries found to carry a pathogenic germline cancer mutation, with coverage aligned to evidence‑based oncology guidelines.